Alnylam Pharmaceuticals (ALNY) Inventory Average (2018 - 2026)

Alnylam Pharmaceuticals' Inventory Average history runs 9 years deep, the most recent figure standing at $83.4 million for Q1 2026.

• Quarterly Inventory Average rose 15.72% year-over-year to $83.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $83.4 million (up 15.72% YoY) and the FY2025 annual result came in at $80.6 million, down 3.83% from the prior year.
• Inventory Average was $83.4 million for Q1 2026 at Alnylam Pharmaceuticals, up from $79.1 million in the prior quarter.
• Across five years, Inventory Average topped out at $130.4 million in Q1 2023 and bottomed at $68.6 million in Q2 2025.
• A 5-year average of $90.7 million and a median of $83.7 million in 2022 frame the typical range for Inventory Average.
• Annual changes were most pronounced in 2023 — Inventory Average surged 58.2% — and 2024, when it retreated 29.79%.
• Alnylam Pharmaceuticals' Inventory Average stood at $122.2 million in 2022, then dropped by 24.35% to $92.5 million in 2023, then retreated by 16.45% to $77.2 million in 2024, then grew by 2.33% to $79.1 million in 2025, then increased by 5.47% to $83.4 million in 2026.
• Business Quant data shows ALNY's Inventory Average at $83.4 million in Q1 2026, $79.1 million in Q4 2025, and $73.5 million in Q3 2025.